EMA (EU)
GUIDANCE FINAL
Concept paper on the revision of the guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease
Published: 6/29/2026Detected: 6/29/2026
Summary preview
Updates EMA clinical evaluation expectations for antifungal agents to better support regulatory claims for treatment/prophylaxis of invasive fungal disease, with particular focus on rare/emerging pathogens, refractory…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
pediatrics
respiratory
clinical
safety
labeling
#invasive fungal disease
#antifungal agents
#rare and emerging pathogens
#refractory disease
#salvage therapy
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026